High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease
Heplisav-B achieved higher rates of seroprotection than those seen with 3-dose recombinant HepB vaccines in patients with IBD and may be the preferred option.
Authors
- Mary S. Hayney (ORCID: https://orcid.org/0000-0003-3307-5634)
- Francis A. Farraye (ORCID: https://orcid.org/0000-0001-6371-2441)
- Freddy Caldera (ORCID: https://orcid.org/0000-0003-1960-6611)
- Fauzia Hollnagel
- Sarah Lazarus (ORCID: https://orcid.org/0000-0002-5629-1009)
- Yash Hegde
Institutions
- University of Wisconsin–Madison (US)
- WinnMed (US)
- Cancer Research And Biostatistics (US)
- Mayo Clinic in Florida (US)
- Hennepin Healthcare Research Institute (US)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1097/mcg.0000000000002098
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- Eli Lilly and Company
- Seqirus